DIGvsIVADigoxin vs. Ivabradine in Heart Failure with Preserved Systolic Function
This observational study aims to compare the effects of Digoxin and Ivabradine on heart function, specifically focusing on both diastolic and systolic functions, in individuals with heart failure who have preserved systolic function.
Drug Data
Collected from today forward - ProspectiveArrhythmias, Cardiac+4
+ Cardiovascular Diseases
+ Heart Diseases
Case-Crossover
Comparing exposures during disease occurrence and non-occurrence in order to assess the short-term effects of triggers.Summary
Study start date: April 1, 2008
Actual date on which the first participant was enrolled.Selected patients had chronic coronary artery disease which had been treated with percutaneous dilatation & stenting and/or aortocoronary bypass. The severity of myocardial ischemia had induced heart failure with diastolic dysfunction and preserved systolic function, and permanent AF. 1 Inclusion criteria: Dyspnea class III NYHA. Abnormal left ventricular relaxation with preserved (≥52%) ejection fraction (LVEF). Patients either in sinus rhythm or with permanent atrial fibrillation. 2. Exclusion criteria: Unstable angina pectoris. Reduced systolic cardiac function (LVEF<52%). Normal diastolic function. Diabetes requiring insulin. Moderate or severe renal or hepatic dysfunction. Technically insufficient echocardiography.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.42 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Case-Crossover
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 60 to 78 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: No need to change concomitant pharmacological therapy in the following months, dyspnea class III NYHA, and abnormal left ventricular relaxation with preserved (≥52%) left ventricular ejection fraction (LVEF). Exclusion Criteria: Unstable myocardial ischemia, reduced systolic cardiac function (LVEF<52%), diabetes mellitus requiring insulin, moderate or severe renal or hepatic dysfunction, or technically insufficient echocardiography.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location